

PCT/AUS 99/06700
IPEA/US 05 JUN 2000

-14-

We claim:

1. A method for treating HIV infections comprising administering a mixture of a reverse transcriptase inhibitor, and/or a protease inhibitor and an integrase inhibitor.
- 5 2. The method of Claim 1 further comprising administering more than one reverse transcriptase inhibitor and/or more than one protease inhibitor.
3. The method of Claim 1 further comprising administering more than one integrase inhibitor.
- 10 4. The method of Claim 2 further comprising administering more than one integrase inhibitor.
5. The method of Claim 1, wherein the integrase inhibitor is selected from a group consisting of chicoric acid 2,3-di(3,4-dihydroxy-dihydroxydihydrocinnamoyl)-tartaric acid, 2,3-di-(3,4-dihydroxybenzoyl)-
15 tartaric acid, 2,3-di-(3,4-dihydroxyphenylacetyl)-tartaric acid, 2,3-di-(3,4,5-trihydroxybenzoyl)-tartaric acid, 2,3-dicaffeoyldiamidopropionic acid, 1,2-dicaffeoyl-glyceric acid, bis,-3,4-dicaffeoyldiamidobenzoic acid, di-3,4-dihydroxybenzylidene succinic acid, di-3,4-dihydrodihydroxybenzylidene succinic acid, 2,3-dicaffeoyl-serine, bis-dicaffeoyl-isoserine and 1,4-dicaffeoyl-
20 lysine

AMENDED SHEET

PCT/US 99/06700
IPEA/US 05 JUN 2000

-15-

6. The method of Claim 1, wherein the reverse transcriptase inhibitor is selected from a group consisting of 2',3'-dideoxycytidine, 2',3'-dideoxyinosine and zidovudine.

7. The method of Claim 1, wherein the protease inhibitor is
5 Nelfinavir.

8. A composition for treating HIV infections comprising a mixture of a reverse transcriptase inhibitor, and/or a protease inhibitor and an integrase inhibitor.

9. The composition of Claim 8, wherein the integrase
10 inhibitor is selected from a group consisting of chicoric acid, 2,3-di(3,4-dihydroxy-dihydroxydihydrocinnamoyl)-tartaric acid, 2,3-di-(3,4-dihydroxybenzoyl)-tartaric acid, 2,3-di-(3,4-dihydroxyphenylacetyl)-tartaric acid, 2,3-di-(3,4,5-trihydroxybenzoyl)-tartaric acid, 2,3-dicaffeoyldiamidopropionic acid, 1,2-dicaffeoyl¹⁹-glyceric acid, bis-3,4-
15 dicaffeoyldiamidobenzoic acid, di-3,4-dihydroxybenzylidene succinic acid, di-3,4-dihydroxybenzylidene succinic acid, 2,3-dicaffeoyl-serine, bis-dicaffeoyl-isoserine and 1,4-dicaffeoyl-lysine

10. The composition of Claim 8, wherein the reverse transcriptase inhibitor is selected from a group consisting of 2',3'-
20 dideoxycytidine, 2',3'-dideoxyinosine and zidovudine.

AMENDED SHEET

-46-

11. The composition of Claim 8, wherein the protease inhibitor is Nelfinavir.

12. The composition of Claim 8 further comprising more than one reverse transcriptase inhibitor and/or more than one protease inhibitor.

5 13. The composition of Claim 8 further comprising more than one integrase inhibitor.

14. The composition of Claim 12 further comprising more than one integrase inhibitor.

15. An integrase inhibitor selected from a group consisting of


10 2,3-di(3,4-dihydroxy-dihydroxydihydrocinnamoyl)-tartaric acid, 2,3-di-(3,4-dihydroxybenzoyl)-tartaric acid, 2,3-di-(3,4-dihydroxyphenylacetyl)-tartaric acid, 2,3-di-(3,4,5-trihydroxybenzoyl)-tartaric acid, 2,3-dicaffeoyldiamidopropionic acid, 1,2,-dicaffeoyl-glyceric acid, bis,-3,4-dicaffeoyldiamidobenzoic acid, di-3,4-dihydroxybenzylidene succinic acid, di-

15 3,4-dihydrodihydroxybenzylidene succinic acid, 2,3-dicaffeoyl-serine, bis-dicaffeoyl-isoserine and 1,4-dicaffeoyl-lysine

AMENDED SHEET

-47-

16. An integrase inhibitor having the formula:




wherein n is between 0 and 4;

wherein R_2 and R_4 are hydrogen

wherein R_1 and R_3 are selected from the group consisting of hydrogen, OR_6 , NR_6 and aralkyl groups;

wherein R_6 is



wherein X is a hydrocarbyl group with from 0 to 10 carbon atoms, Y is selected from $CH=CH$, $N=CH$, $CH=N$, O, S, or NR_7 . m is between 0 and 3, and R_8 is selected from the group consisting of hydrogen, hydroxy, halo, lower alkoxy, alkylcarbonyloxy and alkoxy carbonyloxy or a cyclic carbonate group with hydroxy groups on adjacent carbons; and

wherein R and R_5 are selected from the group consisting of hydrogen, $COOR_7$ and $CONHR_7$;

AMENDED SHEET

-18-

wherein R_7 is selected from the group consisting of hydrogen, alkyl and aralkyl; and

wherein when R and R_5 are COOR_7 and R_7 is hydrogen and R_1 and R_3 are OR_6 , then R_6 and R_8 are hydroxy, m is not 2 and X and Y are not $\text{CH}=\text{CH}$.

5

17. The integrase inhibitor of Claim 16, wherein R_2 and R_4 combine with each other to form a cycloalkyl ring.

18. The integrase inhibitor of Claim 16, wherein R_2 and R_4 are combined with R_1 and R_3 , respectively, to form aromatic rings.

10

19. The integrase inhibitor of Claim 18, wherein the aromatic rings are substituted with from one to three substituents selected from OR_6 and NR_6 groups.

15


20. The integrase inhibitor of Claim 16, wherein when R and R_5 are COOR_7 or CONHR_7 , and R_1 , R_2 and R_3 , R_4 combine to form an arylidene group.

21. The integrase inhibitor of Claim 20, wherein the arylidene group is substituted with from 1 to 3 substituents selected from the group consisting of hydroxy, halo, alkoxy, alkylcarbonyloxy and alkoxyalkylcarbonyloxy.

AMENDED SHEET


-49-

22. An integrase inhibitor having the formula:



wherein R is 1,4-dicaffeoyl, n is between 0 and 6 and L comprises
an amino acid linked by an ester or amide bond.

23. An integrase inhibitor having the formula:



wherein R is 1,4-dicaffeoyl, n is between 0 and 6 and L comprises
a chain of between 1 and 6 carbon atoms.

10

Add
C₂

AMENDED SHEET